ACM
RARE icon

Aquatic Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Aquatic Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.43M Sell
68,222
-19,242
-22% -$433K 0.04% 465
2025
Q4 		$2.01M Sell
87,464
-103,994
-54% -$3.42M 0.06% 372
2025
Q3 		$5.76M Buy
191,458
+84,559
+79% +$2.54M 0.11% 234
2025
Q2 		$3.89M Buy
106,899
+10,691
+11% +$385K 0.08% 298
2025
Q1 		$3.48M Sell
96,208
-6,363
-6% -$265K 0.09% 281
2024
Q4 		$4.32M Buy
102,571
+78,571
+327% +$3.9M 0.12% 224
2024
Q3 		$1.33M Buy
24,000
+5,000
+26% +$255K 0.03% 444
2024
Q2 		$781K Sell
19,000
-1,200
-6% -$51.2K 0.03% 448
2024
Q1 		$943K Buy
+20,200
New +$953K 0.03% 400
2023
Q4 		– Sell
-12,800
Closed -$456K – 1571
2023
Q3 		$456K Buy
12,800
+5,300
+71% +$210K 0.02% 504
2023
Q2 		$346K Buy
7,500
+2,300
+44% +$107K 0.02% 524
2023
Q1 		$209K Buy
+5,200
New +$223K 0.01% 576
2022
Q4 		– Sell
-2,500
Closed -$104K – 1742
2022
Q3 		$104K Buy
+2,500
New +$128K 0.01% 744

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Aquatic Capital Management's RARE Position: Q1 2026 in Review

Aquatic Capital Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 22% in Q1 2026, selling an estimated $433K and leaving 68,222 shares worth $1.43M. The position accounts for 0.04% of the portfolio, ranked #465.

Aquatic Capital Management first reported a position in RARE in Q3 2022 and has held it in 13 quarters since. The position peaked at $5.76M in Q3 2025. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Aquatic Capital Management held 68,222 shares of Ultragenyx Pharmaceutical worth $1.43M as of Q1 2026.
  • Aquatic Capital Management sold 19,242 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $433K.
  • Ultragenyx Pharmaceutical made up 0.04% of Aquatic Capital Management's portfolio in Q1 2026, its #465 holding.
  • Aquatic Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2022 and has held it in 13 quarters since.
  • Aquatic Capital Management's Ultragenyx Pharmaceutical position peaked at $5.76M in Q3 2025.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Aquatic Capital Management's 13F filing for Q1 2026, filed 15 May 2026.